PDCD1 and precursor B-cell acute lymphoblastic leukemia: Finally, our findings reveal that PD-1 targeting can serve as a therapeutic strategy to promote the NK cell-mediated killing of leukemia cells, providing new opportunities for the treatment or prevention of childhood B-ALL.